aprepitant + paroxetine

Aprepitant + paroxetine is a combination of two small molecule drugs. Aprepitant is a neurokinin 1 (NK1) receptor antagonist primarily approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting, acting by blocking substance P from binding to NK1 receptors in the central nervous system. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant, which increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons. This combination has been studied for potential synergistic effects in major depressive disorder; however, clinical trials have shown that adding aprepitant to paroxetine does not enhance antidepressant efficacy compared to paroxetine alone[1]. Both agents are metabolized via CYP3A4 pathways and may interact pharmacokinetically.